OT mobile menu

Search form



Online Database May Help Oncologists Interpret Cancer Mutations More Efficiently

A new tool is available to all clinicians to help better advance precision medicine in the field of oncology. Image © Bruce Rolff/Shutterstock.com 

Recent Content

We spoke with Dr. Garrett-Mayer about concerns regarding statistical probability (P) values and “data dredging” in clinical research.

ERBB2/HER2 mutations appear to be rare but targetable oncogenic drivers in non-small cell lung cancer (NSCLC), according to findings from a small retrospective cohort records analysis

Dr. Roland Seiler presented an analysis of how different bladder cancer molecular subtypes respond to neoadjuvant chemotherapy at the 2017 ASCO Genitourinary Cancer Symposium.

A 34-year-old woman presents with an increase in uterine bleeding. A biopsy is performed during a gynecologic examination. What is your diagnosis?

California researchers are now suggesting that analyzing copies of genes may point to new treatments for ovarian cancer as well as for other tumor types. The researchers contend that targetable genetic changes in tumors should not be limited to mutations.

Researchers at Tulane University are reporting on how cancer is able to overcome p53, a key tumor-suppressing protein.

Ahead of the ASCO-sponsored 2017 Genitourinary Cancers Symposium being held February 16th to February 18th in Orlando, Florida, we spoke with Dr. Ana Aparicio about the role of androgen receptors in prostate cancer.

By clicking Accept, you agree to become a member of the UBM Medica Community.